Data · dataset · 2026
Karlah Mansauda: Overcoming the PEGylation Dilemma in Lipid Nanoparticles for CD47 Silencing: Enhanced Macrophage-Mediated Tumour Clearance
Listed in ZivaHub
<p dir="ltr">
Description
Background
Silencing CD47, a “don’t eat me” signal on breast cancer cells, with small interfering RNA (siRNA), restores macrophage-mediated phagocytosis. Lipid nanoparticles (LNPs) deliver siRNA, but the stabilising PEG layer tends to trap them in endosomes (pH <6) (the PEGylation dilemma). We aim to develop acid-cleavable PEG-lipid LNP (PEGCL-LNP/siCD47) that will ‘shed’ in acidic endosomes.
Read the rest (4 more)
Methods
PEGCL-LNP/siCD47 and non-cleavable controls were formulated and characterised for physicochemical properties, viability, silencing efficiency, and phagocytosis activity. <br>Results: NMR confirmed PEGb-Hz-DPPE. Controls LNP/siCD47 size measured ~150 nm with >80% encapsulation. siRNA above 10 nM reduced cell viability. CD47 silencing reached ~60%; phagocytosis was confirmed; however, endosomal escape was minimal.
PEGCL-LNP/siCD47’s size is larger (~240 nm), PDI (~0.39) and zeta potential (~1.0 mV). Studies on PEG-cleavable LNPs are ongoing. Conclusion: Non-cleavable LNP/siCD47 showed slow transfection (48 h), possibly due to endosomal entrapment.
Ongoing F2-based PEGCL-LNP/siCD47 is expected to improve endosomal escape, CD47 silencing and phagocytosis.</p>
Links
Where it is published
- DOI doi.org/10.17608/k6.auckland.34004574.v2 ↗
DOI / persistent id · from zivahub uct ac za
Catalogue records · 1
- OAI-PMH record api.figshare.com/v2/oai?verb=GetRecord&metadataPrefix=oai_dc&identifier=oai%3Af… ↗
metadata API · from zivahub uct ac za
Topics
- From keywords
- Earth & Environmental Science · Medicine & Health · Pharmaceutical delivery technologies
- Inferred from text
- Cancer 75%
Provenance · 1 source records, 9 field assertions
| Source | Key | Last seen | Raw |
|---|---|---|---|
| ZivaHub | oai:figshare.com:article/34004574 | 5 d ago | JSON v1 |
| Field | Assertion | Extractor | Evidence |
|---|---|---|---|
| access_level | source · zivahub uct ac za | connector:zivahub_uct_ac_za@1.0.0 | |
| concepts[disease].local:disease:cancer | enrichment · zivahub uct ac za | keyword-concept-rules@1.0.0 | title+description (75%) |
| concepts[field].anzsrc:field:321404 | mapping · zivahub uct ac za | vocabulary-mapper@1.0.0 | keywords['Pharmaceutical delivery technologies'] |
| concepts[field].local:field:earth-environmental | mapping · zivahub uct ac za | connector:zivahub_uct_ac_za@1.0.0 | |
| concepts[field].local:field:medicine-health | mapping · zivahub uct ac za | connector:zivahub_uct_ac_za@1.0.0 | |
| description | source · zivahub uct ac za | connector:zivahub_uct_ac_za@1.0.0 | /metadata/dc/description |
| license | source · zivahub uct ac za | connector:zivahub_uct_ac_za@1.0.0 | /metadata/dc/rights |
| publication_date | source · zivahub uct ac za | connector:zivahub_uct_ac_za@1.0.0 | |
| title | source · zivahub uct ac za | connector:zivahub_uct_ac_za@1.0.0 | /metadata/dc/title |